What is Plexiform Bioscience?
Plexiform Bioscience is at the forefront of developing novel, non-invasive treatments for retinal vascular diseases. Their lead product, PB-01, is a pioneering eye drop formula designed to offer a less invasive alternative to traditional procedures like intravitreal injections. By focusing on patient-centric solutions, the company aims to dramatically improve access to effective retinal therapies for a broad patient population. The founding team's expertise, including a vitreoretinal surgeon and a specialized ophthalmologist, provides a strong foundation for clinical development and market penetration.
How much funding has Plexiform Bioscience raised?
Plexiform Bioscience has raised a total of $1.3M across 1 funding round:
Private Equity
$1.3M
Private Equity (2025): $1.3M, investors not publicly disclosed
What's next for Plexiform Bioscience?
The recent major strategic investment signals a pivotal growth phase for Plexiform Bioscience. This capital infusion is expected to accelerate the development and commercialization of PB-01, potentially redefining the standard of care in ophthalmology. The company is poised to expand its clinical trials and prepare for regulatory submissions, leveraging this significant backing to scale operations and reach a wider patient base. Further strategic partnerships may also be explored to enhance market access and therapeutic reach.
See full Plexiform Bioscience company page
